Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.890
+0.020 (0.70%)
Sep 9, 2024, 4:00 PM EDT - Market open
Senti Biosciences Revenue
Senti Biosciences had revenue of $338.00K in the twelve months ending June 30, 2024, down -91.65% year-over-year. In the year 2023, Senti Biosciences had annual revenue of $2.56M, down -40.25%.
Revenue (ttm)
$338.00K
Revenue Growth
-91.65%
P/S Ratio
38.60
Revenue / Employee
$7,042
Employees
48
Market Cap
13.23M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
Dec 31, 2020 | 566.00K | 481.00K | 565.88% |
Dec 31, 2019 | 85.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Flora Growth | 69.01M |
STRATA Skin Sciences | 32.73M |
Psychemedics | 20.79M |
Syra Health | 7.07M |
COSCIENS Biopharma | 4.92M |
SNTI News
- 7 days ago - Senti Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights - GlobeNewsWire
- 5 weeks ago - Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 - GlobeNewsWire
- 2 months ago - Senti Bio Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy - GlobeNewsWire
- 4 months ago - Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - GlobeNewsWire
- 4 months ago - Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - GlobeNewsWire
- 4 months ago - Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) - GlobeNewsWire